# Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Source: https://onco.cc/trials/nct00016276/  
OnCo record `nct00016276` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dexrazoxane, Doxorubicin, Cyclophosphamide, Paclitaxel / nab-paclitaxel, Trastuzumab and Tamoxifen in Inflammatory breast cancer and Breast cancer, run by National Cancer Institute (NCI), recorded as terminated on the registry.

## Summary

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer is a phase 3 interventional study registered as NCT00016276 by National Cancer Institute (NCI), with 396 participants recorded, started 2001-05 and due to reach its primary completion in 2005-03. Interventions recorded: dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis. Conditions recorded: Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer.

Linked to the drug Dexrazoxane because the registry names it among its interventions and Inflammatory breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00016276
- Phase: 3
- Setting: A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 396

## Sources

- ClinicalTrials.gov NCT00016276: https://clinicaltrials.gov/study/NCT00016276

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Inflammatory breast cancer](https://onco.cc/cancers/inflammatory-breast-cancer/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Dexrazoxane](https://onco.cc/drugs/dexrazoxane/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct00016276.json